Section 9F.2.(b) of S.L. 2022-74 directs the pilot program to commence no later than December 1, 2022, and terminate no later than December 1, 2024. DMH/DD/SAS is responsible for determining the number of pilot program sites, the eligibility requirements for participants, and the specific types of PDTs that will be prescribed and evaluated by the pilot program.
Section 9F.2.(c) of S.L. 2022-74 instructs DMH/DD/SAS to submit a report on the impact of the pilot program to the Joint Legislative Oversight Committee on Health and Human Services within six months after the termination of the pilot program. The report must include specified criteria, including a breakdown of expenditures, and identification of the specific PDTs prescribed and an evaluation of their effectiveness.
This section became effective July 1, 2022.